Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.39 USD | +1.33% | +3.26% | +1.42% |
05/04 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
04/04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Business Summary
Number of employees: 904
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 01/16/01 |
Richard Pulik
DFI | Director of Finance/CFO | - | 28/21/28 |
Eric Venker
PSD | President | 37 | 01/14/01 |
Mayukh Sukhatme
PSD | President | 48 | 01/15/01 |
Drew Kramer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Amy Mahery
PRN | Corporate Officer/Principal | - | 01/22/01 |
Kelly Graff
HRO | Human Resources Officer | - | 01/20/01 |
Jo Chen
LAW | General Counsel | - | 01/20/01 |
Srini Ramanathan
PRN | Corporate Officer/Principal | - | 02/22/02 |
Navneet Alag
PRN | Corporate Officer/Principal | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 13/23/13 | |
Keith Manchester
BRD | Director/Board Member | 55 | 01/14/01 |
Dan Gold
BRD | Director/Board Member | 56 | 01/20/01 |
Melissa Epperly
BRD | Director/Board Member | 46 | 29/22/29 |
Mayukh Sukhatme
PSD | President | 48 | 01/15/01 |
Ilan Oren
CHM | Chairman | 40 | 01/14/01 |
Jim Momtazee
BRD | Director/Board Member | - | 01/21/01 |
Matthew Gline
CEO | Chief Executive Officer | 40 | 01/16/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 805,846,006 | 627,008,421 ( 77.81 %) | 0 | 77.81 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
IMMUNOVANT, INC. 54.93% | 79,805,331 | 54.93% | 2,578,510,245 $ |
38,847,462 | 21.64% | 100,226,452 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.42% | 9.06B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- ROIV Stock
- Company Roivant Sciences Ltd.